Skip to main content

Conflict probe turns to Stanford

The irascible conflict of interest hunter, linkurl:Senator Charles Grassley;https://www.the-scientist.com/blog/display/54561/ (R-IA), has set his sights on a Stanford University psychiatrist who's running a federally funded clinical trial on a drug made by the same company in which he owns millions of dollars in stock. The psychiatrist is linkurl:Alan Schatzberg,;https://med.stanford.edu/profiles/Alan_Schatzberg and he is the chair of the psychiatry department at Stanford's School of Medicine. Sc

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
The irascible conflict of interest hunter, linkurl:Senator Charles Grassley;https://www.the-scientist.com/blog/display/54561/ (R-IA), has set his sights on a Stanford University psychiatrist who's running a federally funded clinical trial on a drug made by the same company in which he owns millions of dollars in stock. The psychiatrist is linkurl:Alan Schatzberg,;https://med.stanford.edu/profiles/Alan_Schatzberg and he is the chair of the psychiatry department at Stanford's School of Medicine. Schatzberg owns $6 million of stock in linkurl:Corcept Therapeutics,;https://www.corcept.com/ according to stories in linkurl:__Science__;https://sciencenow.sciencemag.org/cgi/content/full/2008/624/1 and in the linkurl:__San Jose Mercury News__.;https://www.mercurynews.com/lifeandstyleheadlines/ci_9689122?nclick_check=1 The company produces mifepristone, an abortion drug (also known as linkurl:RU-486);https://www.the-scientist.com/article/display/10905/ that is being tested as a depression treatment. Schatzberg is the lead investigator on an NIH-funded study of mifepristone taking place at Stanford, though he is not directly involved in recruiting study subjects or testing patients. Schatzberg and Stanford have attracted Grassley's withering gaze because the Senator, who is the ranking member of the Senate's Committee on Finance, says that the university did not require the researcher to disclose the fact that he owned such a sizable chunk of Corcept Therapeutics stock. Stanford's conflict policies do require investigators to disclose financial conflicts valuing more than $100,000, but for some reason Schatzberg's holdings slipped through the university policy's cracks. "Obviously, $6 million is a dramatically higher number than $100,000 and I am concerned that Stanford may not have been able to adequately monitor the degree of Dr. Schatzberg's conflicts of interest with its current disclosure policies," Grassley wrote in a June 23 linkurl:letter;https://frwebgate1.access.gpo.gov/cgi-bin/PDFgate.cgi?WAISdocID=425632504759+0+1+0&WAISaction=retrieve published in the __Congressional Record__. In the letter, Grassley also outlines instances where Schatzberg received pharmaceutical company payments that he failed to report to Stanford, including an unreported $22,000 Schatzberg got from Johnson and Johnson in 2002. Grassley provides a list of such discrepancies in his letter to Stanford and writes: "The lack of consistency between what Dr. Schatzberg reported to Stanford and what several drug companies reported to me seems to follow a pattern of behavior. More specifically, I have uncovered inconsistent reporting patterns at the University of Cincinnati, and at Harvard University and Mass General Hospital," referring to conflicts among researchers at other institutions Grassley has investigated. A 2006 linkurl:story;https://daily.stanford.edu/article/2006/7/13/potentialConflictsForTrustees in __The Stanford Daily__ stated that Schatzberg co-founded Corcept Therapeutics, and that the University granted the company an exclusive license to develop his patented technologies into FDA-approved treatments. Allegations of conflict between Schatzberg's scientific and financial goals were first raised, according to __The Stanford Daily__ story, when two research psychiatrists at the annual meeting of the American College of Neuropsychopharmacology publicly stated that RU-486's effectiveness in treating depression was questionable and said that Schatzberg's science was compromised by his ties to Corcept Therapeutics.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Related Topics

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems
Optimizing NGS Library Preparation for Reliable Sequencing Data

Optimizing NGS Library Preparation for Reliable Sequencing Data

Covaris
Using TCR Repertoire Sequencing to Advance Immunology Research

Using TCR Repertoire Sequencing to Advance Immunology Research

Miltenyi
Mapping Clonal Mosaicism in Aging Tissues

Mapping Clonal Mosaicism in Aging Tissues

Mission bio

Products

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo
Conceptual image of ice and frost.

The VAULT100 PRO: Inside the most advanced Stirling Ultracold ULT freezer ever built.

Stirling Ultracold logo